Elicio Therapeutics (ELTX) Current Assets (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Current Assets data on file, last reported at $16.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 22.62% year-over-year to $16.2 million; the trailing twelve-month figure through Mar 2026 stood at $16.2 million (down 22.62% YoY), and the FY2025 full-year result was $19.3 million, down 6.68% from the prior year.
• Current Assets for Q1 2026 stood at $16.2 million, down from $19.3 million in the prior quarter.
• Across five years, Current Assets topped out at $76.2 million in Q1 2022 and bottomed at $6.7 million in Q2 2024.
• The 5-year median for Current Assets is $20.9 million (2025), against an average of $28.5 million.
• The widest annual swing landed in 2022, when Current Assets plunged 88.25%; it then soared 237.84% in 2025.
• A 5-year view of Current Assets shows it stood at $10.7 million in 2022, then soared by 52.54% to $16.3 million in 2023, then rose by 26.58% to $20.7 million in 2024, then dropped by 6.68% to $19.3 million in 2025, then dropped by 16.11% to $16.2 million in 2026.
• The last three Current Assets figures came in at $16.2 million (Q1 2026), $19.3 million (Q4 2025), and $21.5 million (Q3 2025), per Business Quant data.

Peer Comparison